Literature DB >> 12412780

Clinical presentation of primary hyperparathyroidism in Europe--nationwide cohort analysis on mortality from nonmalignant causes.

Inga-Lena Nilsson1, Li Yin, Ewa Lundgren, Jonas Rastad, Anders Ekbom.   

Abstract

Primary hyperparathyroidism (PHPT) in developing countries is characterized by severe skeletal and renal complications and apparent mortality. This is in contrast with the Western hemisphere where research interests, rather than characteristics of PHPT, seem to differ between regions. In Europe, the "nontraditional" aspects of mild-to-moderate PHPT have attracted particular attention. These symptoms and signs include risk factors for cardiovascular disease such as hypertension, phenotype IV lipoproteinemia, insulin resistance, cardiac and vascular dysfunction, and morbidity in cardiovascular diseases. Mortality in cardiovascular diseases has been found to be increased in studies that include over 6500 European patients; this risk could not be verified in North American patients. By use of the nationwide Cancer Registry and Causes-of-Death Registry, mortality was analyzed in 10,995 Swedish patients (> 20 years of age) subjected to extirpation of single parathyroid adenoma of PHPT during 1958-1997. The Swedish population standardized for age, sex, and calendar year was used as control. The first postoperative year was excluded from the analysis. In total, the study included 102,515 observed person-years in the patients. Results verify an increased risk of dying after operation for PHPT (standard mortality ratio, 1.2; 95% CI, 1.19-1.27). The increased risk persisted far beyond 15 years postoperatively and occurred in both sexes and in all investigated age groups. Principal causes of excess mortality were cardiovascular diseases, diabetes mellitus, and urogenital diseases in all age groups. However, in patients operated on between 1985 and 1997 (n = 6386), overall mortality did not differ from that of the normal population, although there was maintained excess death in stroke, diabetes mellitus, and urogenital diseases. These findings infer that modern paradigms of surgical treatment normalize the risk of dying from PHPT. This improvement may be a late consequence of liberalized calcium screenings that were introduced about 30 years ago and indicate that operation at early disease stages may offer a survival advantage. An association between diabetes mellitus and PHPT is substantiated.

Entities:  

Mesh:

Year:  2002        PMID: 12412780

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  44 in total

1.  Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism.

Authors:  D Han; S Trooskin; X Wang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

2.  Re: The calcium scare: what would Austin Bradford Hill have thought?

Authors:  M J Bolland; A Grey; I R Reid
Journal:  Osteoporos Int       Date:  2011-09-08       Impact factor: 4.507

3.  Evaluation of left ventricular functions in patients with primary hyperparathyroidism: is there any effect of parathyroidectomy?

Authors:  Alper Kepez; Mehmet Yasar; Murat Sunbul; Cigdem Ileri; Oguzhan Deyneli; Bulent Mutlu; Osman Yesildag; Yelda Basaran
Journal:  Wien Klin Wochenschr       Date:  2017-03-17       Impact factor: 1.704

4.  Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease.

Authors:  Eric N Taylor; Eric B Rimm; Meir J Stampfer; Gary C Curhan
Journal:  Am Heart J       Date:  2011-05       Impact factor: 4.749

5.  Prevalence of primary hyperparathyroidism and impact on bone mineral density in elderly men: MrOs Sweden.

Authors:  Helene Siilin; Ewa Lundgren; Hans Mallmin; Dan Mellström; Claes Ohlsson; Magnus Karlsson; Eric Orwoll; Osten Ljunggren
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

Review 6.  Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.

Authors:  Leonidas H Duntas; Nikolaos Stathatos
Journal:  Endocrine       Date:  2011-03-26       Impact factor: 3.633

7.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

8.  Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy.

Authors:  P Farahnak; M Ring; K Caidahl; L-O Farnebo; M J Eriksson; I-L Nilsson
Journal:  Eur J Endocrinol       Date:  2010-06-18       Impact factor: 6.664

Review 9.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

10.  The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.

Authors:  Christiane Drechsler; Vera Krane; Diana C Grootendorst; Eberhard Ritz; Karl Winkler; Winfried März; Friedo Dekker; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2009-05-27       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.